G. Gallant

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Tanja Trarbach, Markus Moehler, Volker Heinemann et al. · British Journal of Cancer · 2010 · 180 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.

Éduardo Bruera, Scott Ernst, Neil A. Hagen et al. · PubMed · 1998 · 101 citations

Medicine, Oncology, Pharmacology +15

Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

Branimir I. Šikić, S. Gail Eckhardt, G. Gallant et al. · Journal of Clinical Oncology · 2011 · 41 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +16

345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)

Tamar Peretz, Aarón Sulkes, P. Chollet et al. · European Journal of Cancer · 1995 · 39 citations

Medicine, Oncology, Pharmacology +10

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)

Ellen Warner, Rajesh Kumar Goel, J. Chang et al. · British Journal of Cancer · 1998 · 34 citations · Full text

Medicine, Oncology, Pharmacology +4